Screener
Royalty Pharma RPRX Q2 2026 earnings
Reported August 5, 2026 · Before market open
Revenue$773.0MBeat by $14.1M
EPS$1.32Beat by $0.05
Revenue estimate$758.9M
EPS estimate$1.27
“Royalty Pharma delivered strong second quarter results with Royalty Receipts growth of 14%. Our transaction pipeline remains exciting and we continued to bolster our development-stage pipeline in recent months, bringing total Capital Deployment to over $1 billion so far in 2026. Following our acquisition of a royalty on AstraZeneca's cliramitug, our development-stage pipeline now totals 19 potential therapies. Lastly, our strong financial performance has allowed us to raise our top-line guidance for the second time this year, driven by the strength of our diversified portfolio. The fundamental tailwinds supporting our business are compelling and we remain well positioned as a premier capital allocator in life sciences to deliver consistent, compounding growth.”
Next report
Nov 4, 2026 (in 2 months)Revenue estimate$877.4M
EPS estimate$1.16
Financials
Q2 2026Valuation & ratios
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Royalty Pharma report Q2 2026 earnings?
- Royalty Pharma (RPRX) reported Q2 2026 earnings on August 5, 2026 before market open.
- What were Royalty Pharma's Q2 2026 revenue and EPS?
- Royalty Pharma reported revenue of $773.0M and eps of $1.32 for Q2 2026.
- Did Royalty Pharma beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $758.9M by $14.1M. EPS beat the consensus estimate of $1.27 by $0.05.
- How did Royalty Pharma's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 33.6% from $578.7M a year earlier and eps grew 15.8% from $1.14.
- Where can I find Royalty Pharma's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001802768-26-000014) and the 10-Q periodic report (0001802768-26-000015) directly on SEC EDGAR. The filing index links above go to sec.gov.
